Racial Inequity in Prescription of Semaglutide Among Eligible People With HIV
Main finding · Semaglutide receiptResult — go to the resultPrevalence ratio 0.80 95% CI 0.67–0.95Authors' conclusion
We describe inequitable semaglutide use among PWH, with lower initiation rates in eligible Black PWH.
Study context
- Population
- People with HIV in the CNICS cohort at nine sites eligible for semaglutide (BMI ≥30 or HbA1c ≥6.5), 2019–2023eligible people with HIV (PWH)
- Participants
- 11,617 people
- Exposure
- Semaglutide receipt by race and ethnicity among eligible PWH
- Outcome
- Semaglutide receipt among eligible PWH by race and ethnicity
Methodological detailsmulticentre (nine sites), relative risk regression adjusted for demographic characteristics
- Multicentre (nine sites)
- Relative risk regression adjusted for demographic characteristics
Main finding
Semaglutide receipt
Prevalence ratio
0.80
95% CI 0.67–0.95
Black PWHvs White PWH
prevalence ratio 0.80 (95% CI 0.67–0.95)
As reported in the abstract
- Received semaglutide (all eligible PWH)
- 774 (6.7%)
Observational data: associations, not effects.
Further findings
| Outcome | Prevalence ratio (95% CI) | |
|---|---|---|
| Semaglutide receipt, subgroup with HbA1c ≥8.0Black PWHvs White PWH | 0.66 (0.53–0.83) | |
| Semaglutide receipt, subgroup with HbA1c ≥8.0Hispanic PWHvs White PWH | 0.70 (0.53–0.93) | |
| 0.512Prevalence ratio (log scale) |
Eligibility criteria among semaglutide recipients
- Eligible by BMI ≥30
- 92%
- Eligible by HbA1c ≥6.5
- 62%
- Eligible by both criteria
- 54%
Original publication
Racial Inequity in Prescription of Semaglutide Among Eligible People With HIV. Diabetes Care. Published 19 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →